Gland Pharma Mulls Second Site After Penning Initial Henlius Biosimilar Deal
Cost Of Up To $100m Envisioned Via Capacity Expansion; Follows Reddy’s Partnership
India’s Gland Pharma had much to discuss during its financial third-quarter earnings call, including a recent CDMO partnership with China’s Shanghai Henlius Biotech that could lead to the establishment of further manufacturing space to meet demand.
